UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of November 2015

Commission File Number 001-37626

 

 

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

 

 

Not Applicable

(Translation of Registrant’s name into English)

Australia

(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F   þ                Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  ¨                 No  þ

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  ¨                 No  þ

 

 

 

---

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On November 30, 2015, Mesoblast Limited submitted a Change in Director’s Interest Notice form to the Australian Securities Exchange, a copy of which is attached to this report as Exhibit 99.1.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

 

Dated: December 4, 2015

---

INDEX TO EXHIBITS

 

Item
99.1		Change of Director’s Interest Notice, Dr. Ben-Zion Weiner

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

 

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

 

Name of entity Mesoblast Limited

ABN 68 109 431 870

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director		Dr. Ben-Zion Weiner
Date of last notice		16 May 2012 (Initial Director’s Interest Notice)

Part 1 – Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or indirect interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Not applicable
Date of change		27 November 2015 and 30 November 2015
No. of securities held prior to change		80,000 options (issued following approval by shareholders at the 2014 AGM)
Class		Ordinary shares
Number acquired		25,000 ordinary shares (represented by 5,000 American depositary shares) on 27 November 2015 15,000 ordinary shares (represented by 3,000 American depositary shares) on 30 November 2015
Number disposed		N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		US$54,129

 

 

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

---

Appendix 3Y

Change of Director’s Interest Notice

 

 

No. of securities held after change		40,000 ordinary shares (represented by 8,000 American depositary shares) 80,000 options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		On market purchase of American depositary shares

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract		N/A
Nature of interest		N/A
Name of registered holder (if issued securities)		N/A
Date of change		N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed		N/A
Interest acquired		N/A
Interest disposed		N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation		N/A
Interest after change		N/A

Part 3 – +Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?		No
If so, was prior written clearance provided to allow the trade to proceed during this period?		N/A
If prior written clearance was provided, on what date was this provided?		N/A

 

 

+ See chapter 19 for defined terms.

 

Appendix 3Y Page 2		01/01/2011